Brief: Immunovant Reports Q4 Loss Per Common Share Of $0.41

Immunovant

08/06/2022 13:39

June 8 (Reuters) - Immunovant Inc  IMVT.O :
    * IMMUNOVANT ACHIEVES ALIGNMENT WITH FDA ON PLANS FOR PHASE
3
CLINICAL TRIALS OF BATOCLIMAB IN THYROID EYE DISEASE AND REPORTS
FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FISCAL YEAR ENDED
MARCH 31, 2022
    * Q4 LOSS PER SHARE $0.41
    * PLANS TO INITIATE 2 PLACEBO-CONTROLLED PHASE 3 CLINICAL
TRIALS
OF BATOCLIMAB IN THYROID EYE DISEASE IN H2 OF CY 2022
    * ON TRACK TO INITIATE PIVOTAL PHASE 3 CLINICAL TRIAL OF
BATOCLIMAB IN MYASTHENIA GRAVIS (MG), BY END OF JUNE 2022
    * CASH BALANCE OF $494 MILLION AS OF MARCH 31, 2022 EXPECTED
TO
PROVIDE CASH RUNWAY INTO CALENDAR YEAR 2025
    * QTRLY LOSS PER COMMON SHARE $0.41
    * Q4 EARNINGS PER SHARE VIEW $-0.38 -- REFINITIV IBES DATA

Source text for Eikon:  ID:nGNX57kxsm 
Further company coverage:  IMVT.O 

 ((Reuters.Briefs@thomsonreuters.com;))